PMID- 35693002
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220716
IS  - 1664-2295 (Print)
IS  - 1664-2295 (Electronic)
IS  - 1664-2295 (Linking)
VI  - 13
DP  - 2022
TI  - Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying 
      Treatment Outcome in Relapsing-Remitting Multiple Sclerosis.
PG  - 872396
LID - 10.3389/fneur.2022.872396 [doi]
LID - 872396
AB  - Relapsing-remitting multiple sclerosis (RRMS) is a demyelinating disease in which 
      pathogenesis T cells have a major role. Despite the unknown etiology, several 
      risk factors have been described, including a strong association with human 
      leukocyte antigen (HLA) genes. Recent findings showed that HLA class I-G (HLA-G) 
      may be tolerogenic in MS, but further insights are required. To deepen the HLA-G 
      role in MS inflammation, we measured soluble HLA-G (sHLA-G) and cytokines serum 
      level in 27 patients with RRMS at baseline and after 12 and 24 months of 
      natalizumab (NTZ) treatment. Patients were divided into high (sHLA-G>20 ng/ml), 
      medium (sHLA-G between 10 and 20 ng/ml), and low (sHLA-G <10 ng/ml) producers. 
      Results showed a heterogeneous distribution of genotypes among producers, with no 
      significant differences between groups. A significant decrease of sHLA-G was 
      found after 24 months of NTZ in low producers carrying the +3142 C/G genotype. 
      Finally, 83.3% of high and 100% of medium producers were MRI-activity free after 
      24 months of treatment, compared to 63.5% of low producers. Of note, we did not 
      find any correlation of sHLA-G with peripheral cell counts or cytokines level. 
      These findings suggest that serum sHLA-G level may partly depend on genotype 
      rather than peripheral inflammation, and that may have impacted on MRI activity 
      of patients over treatment.
CI  - Copyright (c) 2022 Amoriello, Rizzo, Mariottini, Bortolotti, Gentili, Bonechi, 
      Aldinucci, Carnasciali, Peruzzi, Repice, Massacesi, Fainardi and Ballerini.
FAU - Amoriello, Roberta
AU  - Amoriello R
AD  - Department of Clinical and Experimental Medicine (DMSC), University of Florence, 
      Florence, Italy.
FAU - Rizzo, Roberta
AU  - Rizzo R
AD  - Department of Chemical, Pharmaceutical and Agricultural Sciences, University of 
      Ferrara, Ferrara, Italy.
FAU - Mariottini, Alice
AU  - Mariottini A
AD  - Department of Neurosciences, Drugs and Child Health (NEUROFARBA), University of 
      Florence, Florence, Italy.
FAU - Bortolotti, Daria
AU  - Bortolotti D
AD  - Department of Chemical, Pharmaceutical and Agricultural Sciences, University of 
      Ferrara, Ferrara, Italy.
FAU - Gentili, Valentina
AU  - Gentili V
AD  - Department of Chemical, Pharmaceutical and Agricultural Sciences, University of 
      Ferrara, Ferrara, Italy.
FAU - Bonechi, Elena
AU  - Bonechi E
AD  - Department of Clinical and Experimental Medicine (DMSC), University of Florence, 
      Florence, Italy.
FAU - Aldinucci, Alessandra
AU  - Aldinucci A
AD  - Department of Neurosciences, Drugs and Child Health (NEUROFARBA), University of 
      Florence, Florence, Italy.
FAU - Carnasciali, Alberto
AU  - Carnasciali A
AD  - Department of Clinical and Experimental Medicine (DMSC), University of Florence, 
      Florence, Italy.
FAU - Peruzzi, Benedetta
AU  - Peruzzi B
AD  - Flow Cytometry Diagnostic Center and Immunotherapy (CDCI), Careggi University 
      Hospital, Florence, Italy.
FAU - Repice, Anna Maria
AU  - Repice AM
AD  - Department of Neurosciences, Drugs and Child Health (NEUROFARBA), University of 
      Florence, Florence, Italy.
FAU - Massacesi, Luca
AU  - Massacesi L
AD  - Department of Neurosciences, Drugs and Child Health (NEUROFARBA), University of 
      Florence, Florence, Italy.
AD  - Department Neurology II, Careggi University Hospital, Florence, Italy.
FAU - Fainardi, Enrico
AU  - Fainardi E
AD  - Department of Biomedical, Experimental and Clinical Sciences, University of 
      Florence, Florence, Italy.
FAU - Ballerini, Clara
AU  - Ballerini C
AD  - Department of Clinical and Experimental Medicine (DMSC), University of Florence, 
      Florence, Italy.
LA  - eng
PT  - Journal Article
DEP - 20220525
PL  - Switzerland
TA  - Front Neurol
JT  - Frontiers in neurology
JID - 101546899
PMC - PMC9174986
OTO - NOTNLM
OT  - cytokines
OT  - disease activity
OT  - multiple sclerosis
OT  - natalizumab
OT  - serum sHLA-G
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2022/06/14 06:00
MHDA- 2022/06/14 06:01
PMCR- 2022/05/25
CRDT- 2022/06/13 03:08
PHST- 2022/02/09 00:00 [received]
PHST- 2022/04/25 00:00 [accepted]
PHST- 2022/06/13 03:08 [entrez]
PHST- 2022/06/14 06:00 [pubmed]
PHST- 2022/06/14 06:01 [medline]
PHST- 2022/05/25 00:00 [pmc-release]
AID - 10.3389/fneur.2022.872396 [doi]
PST - epublish
SO  - Front Neurol. 2022 May 25;13:872396. doi: 10.3389/fneur.2022.872396. eCollection 
      2022.